Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.37 |
| ▸ | PNMT | P11086 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4735252 | 0.91 | DRD3 (0.46) | DRD3AKR1C1 | |
| SCHEMBL5641960 | 0.91 | DRD3 (0.43) | MEN1CYP2C9KMT2ADRD3AKR1C1 | |
| SCHEMBL2861574 | 0.90 | DRD3 (0.45) | MEN1KMT2ADRD3AKR1C1OPRM1 | |
| SCHEMBL11878550 | 0.88 | SLC6A2 (0.40) | — | |
| SCHEMBL11736590 | 0.83 | APP (0.41) | MEN1KMT2A | |
| SCHEMBL14164046 | 0.80 | OPRM1 (0.60) | DRD3OPRM1OPRK1OPRL1OPRD1 | |
| SCHEMBL16322010 | 0.80 | CYP2A6 (0.35) | KMT2AOPRM1OPRK1OPRL1OPRD1 | |
| SCHEMBL1759977 | 0.78 | CYP19A1 (0.33) | MAOA | |
| SCHEMBL6583308 | 0.78 | CYP2A6 (0.38) | KMT2AOPRM1OPRK1OPRL1MAOA | |
| SCHEMBL75311 | 0.78 | HSD17B10 (0.38) | MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112679887-B | Bending-resistant silver tube and preparation method thereof | 浙江新洁新材料科技有限公司 | 2022-04-08 | — | — | CN | claimed |
| CN-112795866-A | Aluminum material and preparation method thereof | 浙江贝亚特新材料股份有限公司 | 2021-05-14 | — | — | CN | claimed |
| CN-112679887-A | Bending-resistant silver tube and preparation method thereof | 浙江新洁新材料科技有限公司 | 2021-04-20 | — | — | CN | claimed |
| US-4255447-A | Acaricidal compounds of cyclopropane carboxylic acid derivatives | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 1981-03-10 | — | — | US | claimed |
| US-20240132479-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2024-04-25 | — | — | US | disclosed |
| EP-3577099-B1 | A NOVEL PROCESS FOR THE SYNTHESIS OF 1-ARYL-1-TRIFLUOROMETHYLCYCLOPROPANES | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-01-24 | — | — | EP | disclosed |
| CN-112679887-B | Bending-resistant silver tube and preparation method thereof | 浙江新洁新材料科技有限公司 | 2022-04-08 | — | — | CN | disclosed |
| CN-112795866-A | Aluminum material and preparation method thereof | 浙江贝亚特新材料股份有限公司 | 2021-05-14 | — | — | CN | disclosed |
| CN-112679887-A | Bending-resistant silver tube and preparation method thereof | 浙江新洁新材料科技有限公司 | 2021-04-20 | — | — | CN | disclosed |
| US-10899695-B2 | Process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-01-26 | — | — | US | disclosed |
| US-10899714-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2021-01-26 | — | — | US | disclosed |
| US-20200181090-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | ALCON INC. (CH) | 2020-06-11 | — | — | US | disclosed |
| EP-0305174-B1 | PEPTIDE FK-565 USEFUL FOR CONTROLLING HELMINTHIC PARASITES | PITMAN-MOORE, INC. (US) | 1993-09-15 | — | — | EP | disclosed |
| EP-0305174-A2 | Peptide FK-565 useful for controlling helminthic parasites | PITMAN-MOORE, INC. (US) | 1989-03-01 | — | — | EP | disclosed |
| US-4264606-A | Insecticidal and acaricidal phenylcyclo-propane carboxylic acid derivatives and insecticidal and acaricidal compositions thereof | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1981-04-28 | — | — | US | disclosed |
| US-4264606-A | Insecticidal and acaricidal phenylcyclo-propane carboxylic acid derivatives and insecticidal and acaricidal compositions thereof | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1981-04-28 | — | — | US | disclosed |
| US-4255447-A | Acaricidal compounds of cyclopropane carboxylic acid derivatives | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 1981-03-10 | — | — | US | disclosed |
| US-4255447-A | Acaricidal compounds of cyclopropane carboxylic acid derivatives | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 1981-03-10 | — | — | US | disclosed |
| US-4251662-A | INSECTICIDES, MITICIDES | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1981-02-17 | — | — | US | disclosed |
| US-4215138-A | Insecticidal compounds of phenylcyclopropane carboxylic acid esters | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1980-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181090-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | COQ8A, PGC, AGK | MEN1 3210/4885CYP2C9 2937/4885KMT2A 2030/4885 |
| US-10899714-B2 | 6-aminoisoquinoline compounds | COQ8A, PGC, AGK | MEN1 3210/4885CYP2C9 2937/4885KMT2A 2030/4885 |
| US-10899695-B2 | Process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes | CACNA1G, CACNA1I, CACNA1H | MEN1 1597/4885CYP2C9 286/4885KMT2A 2498/4885 |
| US-20240132479-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | CUTA, DCXR, PLOD3 | MEN1 2632/4885CYP2C9 2174/4885KMT2A 2269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.